Ybcl of uropathogenic escherichia coli suppresses transepithelial neutrophil migration

Infection and Immunity

Volumn 80, Issue 12, 2012, Pages 4123-4132

  Lau, Megan E ^a   Loughman, Jennifer A ^a   Hunstada, David A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BACTERIAL PROTEIN; PERIPLASMIC PROTEIN; UNCLASSIFIED DRUG; YBCL PROTEIN;

ACUTE DISEASE; ARTICLE; CELL MIGRATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; NEUTROPHIL; NONHUMAN; PHENOTYPE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; CARRIER PROTEINS; CELL LINE; CYSTITIS; EPITHELIAL CELLS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; MICE; MICE, INBRED C3H; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTROPHILS; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; URINARY BLADDER; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI; UROTHELIUM;

EID: 84870851475     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00801-12     Document Type: Article

References (38)

1. Anderson GG, Goller CC, Justice S, Hultgren SJ, Seed PC. 2010. Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis. Infect. Immun. 78:963-975.
2. Anderson GG, et al. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105-107.
3. Billips BK, et al. 2007. Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli. Infect. Immun. 75:5353-5360.
4. Blattner FR, et al. 1997. The complete genome sequence of Escherichia coli K-12. Science 277:1453-1474.
5. Brzuszkiewicz E, et al. 2006. How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains. Proc. Natl. Acad. Sci. U. S. A. 103:12879-12884.
6. Chen SL, et al. 2006. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc. Natl. Acad. Sci. U. S. A. 103:5977-5982.
7. Croxen MA, Finlay BB. 2010. Molecular mechanisms of Escherichia coli pathogenicity. Nat. Rev. Microbiol. 8:26-38.
8. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645.
9. Davis JM, Carvalho HM, Rasmussen SB, O'Brien AD. 2006. Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis. Infect. Immun. 74:4401-4408.
10. Davis JM, Rasmussen SB, O'Brien AD. 2005. Cytotoxic necrotizing factor type 1 production by uropathogenic Escherichia coli modulates polymorphonuclear leukocyte function. Infect. Immun. 73:5301-5310.
11. Foxman B. 2010. The epidemiology of urinary tract infection. Nat. Rev. Urol. 7:653-660.
12. Garofalo CK, et al. 2007. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect. Immun. 75:52-60.
13. Haraoka M, et al. 1999. Neutrophil recruitment and resistance to urinary tract infection. J. Infect. Dis. 180:1220-1229.
14. Henson PM, Oades ZG. 1975. Stimulation of human neutrophils by soluble and insoluble immunoglobulin aggregates. Secretion of granule constituents and increased oxidation of glucose. J. Clin. Invest. 56:1053-1061.
15. Hilbert DW, et al. 2008. Uropathogenic Escherichia coli dominantly suppress the innate immune response of bladder epithelial cells by a lipopolysaccharide-and Toll-like receptor 4-independent pathway. Microbes Infect. 10:114-121.
16. Hung CS, Dodson KW, Hultgren SJ. 2009. A murine model of urinary tract infection. Nat. Protoc. 4:1230-1243.
17. Hunstad DA, Justice SS. 2010. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu. Rev. Microbiol. 64:203-221.
18. Hunstad DA, Justice SS, Hung CS, Lauer SR, Hultgren SJ. 2005. Suppression of bladder epithelial cytokine responses by uropathogenic Escherichia coli. Infect. Immun. 73:3999-4006.
19. Justice SS, et al. 2004. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 101:1333-1338.
20. Klumpp DJ, et al. 2001. Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-κB. Infect. Immun. 69:6689-6695.
21. Lipschutz JH, et al. 2001. Analysis of membrane traffic in polarized epithelial cells. Curr. Protoc. Cell Biol. Chapter 15:Unit 15.5.
22. Lorenz K, Lohse MJ, Quitterer U. 2003. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574-579.
23. Loughman JA, Hunstad DA. 2011. Attenuation of human neutrophil migration and function by uropathogenic bacteria. Microbes Infect. 13:555-565.
24. Martinez JJ, Mulvey MA, Schilling JD, Pinkner JS, Hultgren SJ. 2000. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J. 19:2803-2812.
25. Mulvey MA, et al. 1998. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282:1494-1497.
26. Mulvey MA, Schilling JD, Hultgren SJ. 2001. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69:4572-4579.
27. Murphy KC, Campellone KG. 2003. Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli. BMC Mol. Biol. 4:11. doi:10.1186/1471-2199-4-11.
28. Mysorekar IU, Hultgren SJ. 2006. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl. Acad. Sci. U. S. A. 103:14170-14175.
29. Nicholson TF, Watts KM, Hunstad DA. 2009. OmpA of uropathogenic Escherichia coli promotes postinvasion pathogenesis of cystitis. Infect. Immun. 77:5245-5251.
30. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. 2007. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 4:e329. doi:10.1371/journal.pmed.0040329.
31. Schilling JD, Lorenz RG, Hultgren SJ. 2002. Effect of trimethoprimsulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect. Immun. 70:7042-7049.
32. Serre L, et al. 2001. Crystal structures of YbhB and YbcL from Escherichia coli, two bacterial homologues to a Raf kinase inhibitor protein. J. Mol. Biol. 310:617-634.
33. Welch RA, et al. 2002. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 99:17020-17024.
34. Yamaguchi K, Yu F, Inouye M. 1988. A single amino acid determinant of the membrane localization of lipoproteins in E. coli. Cell 53:423-432.
35. Yeung K, et al. 1999. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401:173-177.
36. Yeung KC, et al. 2001. Raf kinase inhibitor protein interacts with NF-κBinducing kinase and TAK1 and inhibits NF-κB activation. Mol. Cell. Biol. 21:7207-7217.
37. Zhanel GG, et al. 2005. Antibiotic resistance in outpatient urinary isolates:final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int. J. Antimicrob. Agents 26:380-388.
38. Zhou G, et al. 2001. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J. Cell Sci. 114:4095-4103.